SIP
DYN icon

Stoneridge Investment Partners’s Dyne Therapeutics DYN Stock Holding History

Stoneridge Investment Partners’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$301K Buy
+16,611
New +$286K 0.22% 86

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Stoneridge Investment Partners's DYN Position: Q1 2026 in Review

Stoneridge Investment Partners opened a new position in Dyne Therapeutics (DYN) in Q1 2026: 16,611 shares worth $301K. The stake represents 0.22% of the portfolio and ranks #86 among its holdings.

227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • Stoneridge Investment Partners held 16,611 shares of Dyne Therapeutics worth $301K as of Q1 2026.
  • Dyne Therapeutics was a new Stoneridge Investment Partners position in Q1 2026.
  • Dyne Therapeutics made up 0.22% of Stoneridge Investment Partners's portfolio in Q1 2026, its #86 holding.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Stoneridge Investment Partners's 13F filing for Q1 2026, filed 6 May 2026.